Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Semin Oncol. 2002 Feb; 29(1 Suppl 2):48-55.
-
Actins
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols
-
Chromosomes, Human, Pair 14
-
Chromosomes, Human, Pair 18
-
Dexamethasone
-
DNA
-
Humans
-
Lymphoma, Follicular
-
Lymphoma, Non-Hodgkin
-
Mitoxantrone
-
Neoplasm, Residual
-
Polymerase Chain Reaction
-
Rituximab
-
Translocation, Genetic
-
Vidarabine